These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18159149)

  • 21. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
    Chien RN; Liaw YF; Atkins M
    Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
    Guptan RC; Thakur V; Kazim SN; Sarin SK
    J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
    Chien RN; Liaw YF
    Antivir Ther; 2006; 11(7):947-52. PubMed ID: 17302259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
    Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY
    Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.
    Wu F; Wu MJ; Zhuge XL; Zhu SM; Zhu B
    Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):172-6. PubMed ID: 22484586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Serum ALT and HBV DNA levels in patients with HBeAg-negative chronic hepatitis B].
    Kim KH; Na IH; Cha JM; Cho YK; Park SY; Kim HP; Song CS; Heo J; Cho M
    Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):284-92. PubMed ID: 14695695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients.
    Peng CY; Hsieh TC; Hsieh TY; Tseng KC; Lin CL; Su TH; Tseng TC; Lin HH; Wang CC; Kao JH
    J Formos Med Assoc; 2015 Apr; 114(4):308-13. PubMed ID: 24315616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients.
    Wang CC; Liu CJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2007 Mar; 27(2):235-9. PubMed ID: 17311619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.
    Alexander G; Baba CS; Chetri K; Negi TS; Choudhuri G
    BMC Gastroenterol; 2005 Sep; 5():29. PubMed ID: 16164746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].
    Yao GB; Wang BE; Cui ZY; Yao JL; Zeng MD
    Zhonghua Nei Ke Za Zhi; 2003 Jun; 42(6):382-7. PubMed ID: 12895320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term lamivudine therapy for chronic hepatitis B in patients with and without cirrhosis.
    Oh JM; Kyun J; Cho SW
    Pharmacotherapy; 2002 Oct; 22(10):1226-34. PubMed ID: 12389873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
    Zhu SS; Dong Y; Zhang HF; Wang LM; Xu ZQ; Zhang M; Gan Y; Chen DW; Wang FC; Yan JG; Zhao P
    Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):604-609. PubMed ID: 31594077
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hepatitis B virus genotypes and the response to lamivudine therapy].
    Zalewska M; Domagała M; Simon K; Gładysz A
    Pol Arch Med Wewn; 2005 Dec; 114(6):1190-9. PubMed ID: 16789488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
    Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
    Peters MG; Hann Hw Hw; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray Df Df; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL
    Gastroenterology; 2004 Jan; 126(1):91-101. PubMed ID: 14699491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.